Latest COPD Treatment: Miracle As It Promises Permanent Relief For Patients

Adding Roche’s (RHHVF, -0.49%) immunotherapy Tecentriq to older drugs doubled the percentage of lung cancer patients who survived a year without their disease advancing, an outcome some experts labeled unprecedented.Thirty-seven percent of patients in a closely watched clinical trial who received Tecentriq, Avastin and chemotherapy reached the one-year mark without their Lung Cancer progressing (PFS), according to data released on Thursday.For patients getting only Avastin and chemotherapy, that fell to 18%.

 

 

Roche’s announcement in November that its Impower 150 trial had broadly succeeded in first-line lung cancer patients helped spur a one-day, $12 billion rally in the Basel-based drugmaker’s market capitalization.Roche Chief Executive Severin Schwan sees an opportunity to leap-frog ahead as competitors still await their own lung cancer combination trial results.“This is very, very promising,” Dr Solange Peters, the head of Medical Oncology at the Centre Hospitalier Universitaire Vaudois in Lausanne, Switzerland, said on the latest results.“Doubling PFS (progression-free survival) at one year is something we have not seen with any targeted therapy in unselected patients to date.”


LEAVE A REPLY

Please enter your comment!
Please enter your name here